Sequenom's Q2 Revenues Rise 17 Percent as It Names T21 Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its second-quarter revenues jumped 17 percent as sales rose for its genetic analysis products and diagnostic services.

The San Diego-based molecular diagnostics developer brought in total revenues of $13.3 million for the three months ended June 30, compared to revenues of $11.4 million for the second quarter of 2010. It missed Wall Street's estimate of $13.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.